"I hardly recognized the buoyant person I’d become," says this New York Times opinion piece writer on her experience treating her severe depression with Ketamine.
Learning about medical cannabis can be challening for patients. It's even harder for physicians, who traditionally rely on medical studies and sources that often can not be accessed by the public. However, because there is limited data on medical marijuana due to its current legal status and lack of funding from industry, I have found it challenging to make sure I am using reliable data to educate myself and my patients.
Here is an article where I am featured that describes the scope of the problem.
You Might Also Enjoy...
"I hardly recognized the buoyant person I’d become," says this New York Times opinion piece writer on her experience treating her severe depression with Ketamine.
While we are still in the middle of a pandemic, it's important to keep your lungs as healthy as possible.
Warnings about limiting activity are not an over-reaction. This is a serious and deadly disease and we need to change our activities, no matter how difficult.
Spravato (nasal esketamine) is a new treatment for patients who have tried multiple medications, but failed to find relief (known as treatment resistant depression).
In many states, patients are getting therapy recommendations from non-clinicians, which may have some serious risks.
